<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442557</url>
  </required_header>
  <id_info>
    <org_study_id>DC-001</org_study_id>
    <nct_id>NCT02442557</nct_id>
  </id_info>
  <brief_title>Safety and Dose-finding Study of DC-TAB in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and T-cell Tolerizing Effect of DC-TAB in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delta Crystallon BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Delta Crystallon BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety and appropriate dose of DC-TAB for selective&#xD;
      immune tolerance induction in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled, dose-escalation study of DC-TAB&#xD;
      in healthy human volunteers. DC-TAB is a solution of the small heat-shock protein alpha&#xD;
      B-crystallin for intravenous injection, designed to induce selective immunological tolerance&#xD;
      as a treatment for multiple sclerosis. In this first-in-man study, DC-TAB is administered to&#xD;
      healthy subjects in varying doses and for a varying number of times, after which safety and&#xD;
      tolerability is evaluated, as well as the impact of the treatment on antigen-specific&#xD;
      responses by peripheral blood T cells and serum antibodies. Blood samples are additionally&#xD;
      collected to measure serum concentrations of DC-TAB, and to determine the rate of clearance&#xD;
      from the circulation. The study is double blind and placebo-controlled to strengthen the&#xD;
      significance especially of immunological evaluations.&#xD;
&#xD;
      The study consists of two parts. In Part 1, subjects receive a single dose of DC-TAB or&#xD;
      placebo whereas in Part 2, (different) subjects receive DC-TAB or placebo on 3 consecutive&#xD;
      days. In Part 1, four groups of subjects (n=10) are studied in a single dose, dose-escalation&#xD;
      design. Each group of subjects are randomized to receive either DC-TAB (n=8) or placebo (n=2)&#xD;
      once. In Part 2, three groups of subjects (n=12) are studied in a multiple dose,&#xD;
      dose-escalation design. Each group of subjects are randomized to receive either DC-TAB (n=9)&#xD;
      or placebo (n=3) once daily on 3 consecutive days. The next higher dose group in each part of&#xD;
      the study only starts once safety data up to 4 days for Part 1, up to 8 days for Part 2 of&#xD;
      the previous dose group have been reviewed and have raised no safety concerns. Part 2 is&#xD;
      started once all safety data of Part 1 have been reviewed. Immunological effects of the&#xD;
      treatments are evaluated over a period of 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>28 days</time_frame>
    <description>Frequency of</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antigen-specific T-cell response</measure>
    <time_frame>28 days</time_frame>
    <description>Strength of antigen-specific T-cell responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (serum levels of DC-TAB)</measure>
    <time_frame>24 h</time_frame>
    <description>Serum levels of DC-TAB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability (Injection site abnormalities)</measure>
    <time_frame>28 days</time_frame>
    <description>Injection site abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody responses</measure>
    <time_frame>28 days</time_frame>
    <description>Serum levels of anti-DC-TAB antibodies</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>single dose 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single intravenous injection of 4 mg DC-TAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose 12.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single intravenous injection of 12.5 mg DC-TAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single intravenous injection of 25 mg DC-TAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose 37.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single intravenous injection of 4 mg DC-TAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a single intravenous injection of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple dose 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>three consecutive daily intravenous injections of 10 mg DC-TAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple dose 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>three consecutive daily intravenous injections of 25 mg DC-TAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple dose 37.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>three consecutive daily intravenous injections of 37.5 mg DC-TAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple dose placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>three consecutive daily intravenous injections of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant human alpha B-crystallin</intervention_name>
    <description>intravenous injection</description>
    <arm_group_label>multiple dose 10 mg</arm_group_label>
    <arm_group_label>multiple dose 25 mg</arm_group_label>
    <arm_group_label>multiple dose 37.5 mg</arm_group_label>
    <arm_group_label>single dose 12.5 mg</arm_group_label>
    <arm_group_label>single dose 25 mg</arm_group_label>
    <arm_group_label>single dose 37.5 mg</arm_group_label>
    <arm_group_label>single dose 4 mg</arm_group_label>
    <other_name>HspB5; CRYAB; DC-TAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo comparator</intervention_name>
    <description>intravenous injection</description>
    <arm_group_label>multiple dose placebo</arm_group_label>
    <arm_group_label>single dose placebo</arm_group_label>
    <other_name>phosphate-buffered saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  Signed the written informed consent form before first screening procedure&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 55 years&#xD;
&#xD;
          -  In general good health in the opinion of the investigator&#xD;
&#xD;
          -  BMI between 20.0 and 28.0 kg/m2&#xD;
&#xD;
          -  Use of adequate and stable contraception for 3 months prior to study initiation,&#xD;
             during the course of the study and 30 days thereafter. Sexually active males must use&#xD;
             a condom. Sexually active females must use double-barrier contraception or hormonal&#xD;
             contraceptive (oral, transdermal, vaginal ring, implants), or must have undergone&#xD;
             clinically documented total hysterectomy and/or oophorectomy, surgical sterilization&#xD;
             or be postmenopausal defined by amenorrhea for at least 12 months and confirmed with a&#xD;
             FSH higher than 40 IU/mL.&#xD;
&#xD;
          -  If subjects claim abstinence as their method of contraception, they must be willing to&#xD;
             agree to use condoms if they become sexually active from 14 days prior to the first&#xD;
             dose of the study drug through 90 days beyond the conclusion of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, women planning to become pregnant and breastfeeding women&#xD;
&#xD;
          -  Subjects with a history of MS in first grade family members&#xD;
&#xD;
          -  A history of or currently active clinically significant cardiac (including clinically&#xD;
             significant ECG abnormalities in the opinion of the PI), pulmonary, gastrointestinal,&#xD;
             hepatic, renal, pancreatic, or neurological disease&#xD;
&#xD;
          -  ALT, AST and/or gamma-GT above 3 times the upper limit of normal&#xD;
&#xD;
          -  Serum creatinine above 1.5 times the upper limit of normal&#xD;
&#xD;
          -  Amylase above 1.5 times the upper limit of normal&#xD;
&#xD;
          -  Hemoglobin &lt; 7.0 mmol/L for females and &lt; 8 mmol/L for males; leucocytes &gt; 20*109/L or&#xD;
             &lt; 3.5*109/L; platelets &lt; 125*109/L&#xD;
&#xD;
          -  SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg&#xD;
&#xD;
          -  Known or suspected hypersensitivity to any component of DC-TAB&#xD;
&#xD;
          -  Known or suspected impairment of the immune system&#xD;
&#xD;
          -  Acute respiratory or other active infections or illnesses&#xD;
&#xD;
          -  Fever (oral temperature &gt; 38.0 °C on day 1)&#xD;
&#xD;
          -  Blood donation or significant blood loss within 90 days of first study medication&#xD;
             dosing.&#xD;
&#xD;
          -  Plasma donation within 7 days of first study medication dosing&#xD;
&#xD;
          -  Recipients of blood or blood products in the last 6 months&#xD;
&#xD;
          -  Participation in another clinical study within 90 days of the start of this trial or&#xD;
             planning participation in another clinical trial during this study or in the 4 weeks&#xD;
             after last visit&#xD;
&#xD;
          -  Taking immunosuppressive agents, corticosteroids, anti-allergic, anti-coagulation or&#xD;
             anti-platelet medication&#xD;
&#xD;
          -  History of drug addiction (positive drug screen) or excessive use of alcohol (weekly&#xD;
             intake more than 28 units of alcohol), or psychological or other emotional problems&#xD;
             that are likely to invalidate informed consent, or limit the ability of the subject to&#xD;
             comply with the protocol requirements&#xD;
&#xD;
          -  Positive HIV1, or HIV2 serology&#xD;
&#xD;
          -  Positive results from the hepatitis serology which indicates acute or chronic&#xD;
             hepatitis B or hepatitis C&#xD;
&#xD;
          -  Positive alcohol breath test&#xD;
&#xD;
          -  Vaccination with any vaccine within 4 weeks prior to dosing of the study medication&#xD;
&#xD;
          -  Any physical condition that would, in the opinion of the investigator, place the&#xD;
             subject at an unacceptable health risk or risk of injury or render the subject unable&#xD;
             to meet the requirements of the protocol&#xD;
&#xD;
          -  History of serious adverse reactions or hypersensitivity to any medicinal product&#xD;
&#xD;
          -  Smoking &gt; 5 cigarettes/day or unable to refrain from smoking while confined to the CPU&#xD;
&#xD;
          -  Use of prescription, over-the-counter (OTC), herbal supplements (excluding hormonal&#xD;
             contraceptives, one-a-day vitamins, acetaminophen) within 14 days prior to the first&#xD;
             dose of study drug).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Floris Höppener, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kendle International</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 1, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alpha B-crystallin</keyword>
  <keyword>immune tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

